Chapters authored
Laparoscopy for the Undescended Testes
Part of the book: Advanced Laparoscopy
Therapeutic Applications of Monoclonal Antibodies in Urologic-Oncology Management - An Update
The idea of utilizing immunotherapy for the treatment of cancers has been appealing to scientists and clinicians for over a several decades. Immunotherapy for cancers encompasses knowledge gained from a wide range of disciplines and has the potential to procure the ‘magic bullet’ for the treatment of cancer. Monoclonal antibody-based treatment of cancer has been recognized as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumours in the last 20 years. The discovery of hybridoma technology in late 1975 and the development of chimeric, humanized, and human antibodies have increased the availability and utility of immunotherapy for the treatment of cancer. Metastatic or recurrent cancer continues to be the bane of the urological oncologist. Despite recent improvements in therapeutic management and outcomes for clinically localized disease overall survival rate in patients with the majority of metastatic and recurrent genitourinary malignancies remains relatively unchanged. By targeting tumours through specific or associated antigens, it is possible to selectively eliminate tumour cells and maintain an acceptable toxicity profile. Therapeutic antibodies that target immune cells are also being developed with the goal of breaking local tolerance and stimulating the patient’s anti-tumor immune response. As with other treatment modalities, immunotherapy is far from perfect and requires additional study to optimize clinical response and overcome therapeutic resistance. Modern advances in the field of immunotherapy hold the promise of providing the clinical urologist/oncologist with new tools to fight urological cancer. However, the literature on monoclonal antibody-based immunotherapy with a particular emphasis on target antigens, monoclonal antibody design and potential applications in the field of urology is limited. Hence, the present chapter focuses on the applications of Immunotherapy using monoclonal antibodies for urologic oncology settings such as prostate, bladder, renal, testicular and penile with a hope to highlight its clinical efficacy and also its mechanisms of action in each of these cancer types.
Part of the book: Monoclonal Antibodies
Overview of Primary Cell Culture Models in Preclinical Research of Prostate and Bladder Cancer
The number of patients diagnosed with prostate and bladder cancer is increasing worldwide and one of the most important challenges remains the development of effective, safe and economically viable antitumor drugs. Clinical approval for drugs tested in preclinical studies enabling them to enter phase I clinical trials is essential. Cell lines are in vitro model systems that are widely used in different fields of medical research, especially basic cancer research and drug discovery. Their usefulness is primarily linked to their ability to provide an indefinite source of biological material for experimental purposes. Under the right conditions and with appropriate controls, authenticated cancer cell lines retain most of the genetic properties of the cancer of origin. Studies conducted during the initial development of drugs such as toxicity, corrosion and drug activity were carried out on animals; however, in the past two decades, alternatives have been sought due to the fact that animals do not effectively model to human in vivo conditions and unexpected responses are observed in the studies. Also, more than 100 million animals were used and billion dollars were spent for animal toxicity experiments. Cell culture studies made positive contributions to the initial development of drugs and is highly desirable, as it provides systems for ready, direct access and evaluation of tissues. Contrary to animal studies, less cost and the need for low drug and a short response time are the characteristics for in vitro cell culture methods. In vitro tumor models are a necessary tool, in not only the search for new substances showing antitumor activity but additionally for assessing their effectiveness. This chapter reviews the main features of primary cancer cell cultures, provides an overview of the different methods for their selection and management, and summarizes the wide range of studies that can be performed with them to improve the understanding of prostate and bladder cancer preclinical treatment processes.
Part of the book: Cell Culture
Reproductive Toxicology: An Update
Human reproduction and development is a succession of symbiotic events. Nearly, at every point of this phenomenon found to be the principle target of one or more reproductive toxicants. Chemical agents, physical factors, as well as biological intruders can pose antagonistic effects on reproductive potential of an organism. The pathways are different viz., either damaging embryo and sometimes fetus or inducing mutation in a parent’s germ cell. The outcomes are declined fertility to impulsive abortion, functional discrepancies, developmental retardation, structural anomalies, etc. It is a now essential to establishing proper databases for reproductive and developmental toxicity chemicals, physical and biological factors including appropriate awareness among the society. Although many in vitro and in vivo toxicology studies are in pipeline which are independent studies but combination with other hazardous studies could give us an accurate numbers.
Part of the book: Male Reproductive Anatomy